for-phone-onlyfor-tablet-portrait-upfor-tablet-landscape-upfor-desktop-upfor-wide-desktop-up

Allergy Therapeutics plc

AGY.L

Latest Trade

11.32GBp

Change

-0.33(-2.83%)

Volume

91,183

Today's Range

--

 - 

--

52 Week Range

7.30

 - 

15.75

As of on the London Stock Exchange (LON) ∙ Minimum 15 minute delay

Pricing

Previous Close
11.65
Open
11.65
Volume
91,183
3M AVG Volume
21.39
Today's High
--
Today's Low
--
52 Week High
15.75
52 Week Low
7.30
Shares Out (MIL)
636.17
Market Cap (MIL)
74.11
Forward P/E
--
Dividend (Yield %)
--

Next Event

Half Year 2020 Allergy Therapeutics PLC Earnings Release

Latest Developments

More

Allergy Therapeutics Sees Higher HY Rev

Allergy Therapeutics Posts FY Revenue Up 8%

Allergy Therapeutics Expects FY Overheads To Be In Line With Market Expectations

for-phone-onlyfor-tablet-portrait-upfor-tablet-landscape-upfor-desktop-upfor-wide-desktop-up

About Allergy Therapeutics plc

Allergy Therapeutics Plc is a pharmaceutical company. The Company focuses on the treatment and prevention of allergy with aluminum-free products. The Company's segments are Central Europe, which includes segments, such as Germany, Australia, Switzerland and the Netherlands; Southern Europe, which includes Italy and Spain; the United Kingdom, and Rest of World. The Company provides information to healthcare professionals about the prevention, diagnosis and treatment of allergic conditions with focus on allergy vaccination, which is also known as specific immunotherapy or desensitization therapy. The Company's products include Pollinex Trees, Pollinex Grasses+Rye, Skin Prick Testing and diagnostic products. Its vaccines trade under various brand names, such as Pollinex Quattro, Polligoid and TA Graser Top. It uses specialized systems to process the Tyrosine to form a suspension microcrystalline tyrosine (MCT) that is combined with some of its subcutaneous injected therapies.

Contact Info

Dominion Way

+44.1903.844700

http://www.allergytherapeutics.com/

Executive Leadership

Peter Sinclair Jensen

Non-Executive Independent Chairman of the Board

Manuel Llobet

Chief Executive Officer, Executive Director

Nicolas Alexander Ulrich Wykeman

Chief Financial Officer, Executive Director

Scott Leinenweber

Non-Executive Independent Director

Babatunde Tunde Otulana

Non-Executive Independent Director

Key Stats

2.00 mean rating - 3 analysts
Sell
Hold
Buy
Revenue (MM, GBP)

2017

0.1K

2018

0.1K

2019

0.1K

2020(E)

0.1K
EPS (GBp)

2017

-0.420

2018

-1.270

2019

0.520

2020(E)

-0.656
Price To Earnings (TTM)
24.89
Price To Sales (TTM)
1.01
Price To Book (MRQ)
1.97
Price To Cash Flow (TTM)
13.34
Total Debt To Equity (MRQ)
6.49
LT Debt To Equity (MRQ)
4.64
Return on Investment (TTM)
7.88
Return on Equity (TTM)
5.80

Latest News

Latest News

BRIEF-Ergomed Says Co-Development Partnership With Allergy Therapeutics

* MULTI-PRODUCT, MULTI-STUDY CO-DEVELOPMENT PARTNERSHIP WITH ALLERGY THERAPEUTICS PLC

BRIEF-Allergy Therapeutics posts FY pre-tax loss 1.9 mln stg

* FY REVENUE 55.5 MILLION STG VERSUS 48.5 MILLION STG YEAR AGO

BRIEF-Allergy Therapeutics announces rise in HY revenue

* HY revenue increased by 18 pct at constant currency to 34.2 mln pounds (H1 2016: 29.0 mln pounds)

Quote and financial data from Refinitiv. Fund performance data provided by Lipper. All quotes delayed a minimum of 15 minutes.

for-phone-onlyfor-tablet-portrait-upfor-tablet-landscape-upfor-desktop-upfor-wide-desktop-up